133 related articles for article (PubMed ID: 38458187)
1. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
Barisic D; Chin CR; Meydan C; Teater M; Tsialta I; Mlynarczyk C; Chadburn A; Wang X; Sarkozy M; Xia M; Carson SE; Raggiri S; Debek S; Pelzer B; Durmaz C; Deng Q; Lakra P; Rivas M; Steidl C; Scott DW; Weng AP; Mason CE; Green MR; Melnick A
Cancer Cell; 2024 Apr; 42(4):583-604.e11. PubMed ID: 38458187
[TBL] [Abstract][Full Text] [Related]
2. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
3. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
4. ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF.
Chandler RL; Brennan J; Schisler JC; Serber D; Patterson C; Magnuson T
Mol Cell Biol; 2013 Jan; 33(2):265-80. PubMed ID: 23129809
[TBL] [Abstract][Full Text] [Related]
5. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
7. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
8. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
Barisic D; Chin CR; Meydan C; Teater M; Tsialta I; Mlynarczyk C; Chadburn A; Wang X; Sarkozy M; Xia M; Carson SE; Raggiri S; Debek S; Pelzer B; Durmaz C; Deng Q; Lakra P; Rivas M; Steidl C; Scott DW; Weng AP; Mason CE; Green MR; Melnick A
Cancer Cell; 2024 Apr; 42(4):720-722. PubMed ID: 38593783
[No Abstract] [Full Text] [Related]
9. SWI/SNF regulation of germinal center fate and lymphomagenesis.
Sievers Q; Abdel-Wahab O
Cancer Cell; 2024 Apr; 42(4):507-509. PubMed ID: 38458185
[TBL] [Abstract][Full Text] [Related]
10. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
11. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
[TBL] [Abstract][Full Text] [Related]
12. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
14. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice.
Mathur R; Alver BH; San Roman AK; Wilson BG; Wang X; Agoston AT; Park PJ; Shivdasani RA; Roberts CW
Nat Genet; 2017 Feb; 49(2):296-302. PubMed ID: 27941798
[TBL] [Abstract][Full Text] [Related]
15. The SWI/SNF BAF-A complex is essential for neural crest development.
Chandler RL; Magnuson T
Dev Biol; 2016 Mar; 411(1):15-24. PubMed ID: 26806701
[TBL] [Abstract][Full Text] [Related]
16. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
17. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
[TBL] [Abstract][Full Text] [Related]
18. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
Deng Q; Lakra P; Gou P; Yang H; Meydan C; Teater M; Chin C; Zhang W; Dinh T; Hussein U; Li X; Rojas E; Liu W; Reville PK; Kizhakeyil A; Barisic D; Parsons S; Wilson A; Henderson J; Scull B; Gurumurthy C; Vega F; Chadburn A; Cuglievan B; El-Mallawany NK; Allen C; Mason C; Melnick A; Green MR
Cancer Cell; 2024 Apr; 42(4):605-622.e11. PubMed ID: 38458188
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
[TBL] [Abstract][Full Text] [Related]
20. ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers.
Reske JJ; Wilson MR; Armistead B; Harkins S; Perez C; Hrit J; Adams M; Rothbart SB; Missmer SA; Fazleabas AT; Chandler RL
BMC Biol; 2022 Sep; 20(1):209. PubMed ID: 36153585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
